{
    "clinical_study": {
        "@rank": "159917", 
        "arm_group": {
            "arm_group_label": "sebelipase alfa", 
            "arm_group_type": "Experimental", 
            "description": "Intravenous infusion of sebelipase alfa: 1mg/kg every other week"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of sebelipase alfa in a broad population of\n      patients with lysosomal acid lipase deficiency (LALD)."
        }, 
        "brief_title": "Safety and Efficacy Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Lysosomal Acid Lipase Deficiency", 
        "condition_browse": {
            "mesh_term": "Wolman Disease"
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to evaluate the safety of intravenous infusions of\n      sebelipase alfa in a more broad population of LALD patients than previously studied.   Such\n      patients may have been excluded from enrollment in other studies of LALD because of age,\n      disease progression, previous treatment by hematopoietic stem cell or liver transplantation,\n      less common disease manifestations, or disease characteristics that would preclude\n      participation in a placebo-controlled study. This open-label study will include infants >8\n      months, children and adults. Eligible patients will receive sebelipase alfa at a dose of 1\n      mg/kg every other week."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Patient will be > 8 months of age at the time of dosing.\n\n          2. Confirmation of LALD diagnosis as determined by the central lab.\n\n          3. Patients > 8 months but < 4 years of age at Screening will have at least 1 of the\n             following documented clinical manifestations of LALD:\n\n             Dyslipidemia\n\n               -  Elevated transaminases (ALT \u22651.5x ULN)\n\n               -  Impaired growth\n\n               -  Suspected malabsorption\n\n               -  Other clinical manifestation of LALD\n\n          4. Patients \u2265 4 years of age at Screening will have at least 1 of the following\n             documented clinical manifestations of LALD:\n\n               -  Evidence of advanced liver disease\n\n               -  Histologically confirmed disease recurrence in patients with past liver or\n                  hematopoietic transplant\n\n               -  Persistent dyslipidemia\n\n               -  Suspected malabsorption\n\n               -  Other clinical manifestation of LALD\n\n        Key Exclusion Criteria:\n\n          1. Patient has known causes of active liver disease other than LALD which have not been\n             adequately treated.\n\n          2. Patient received a hematopoietic stem cell or liver transplant <2 years from the time\n             of dosing.\n\n          3. Patient with co-morbidities other than complications due to LALD which are\n             irreversible or associated with a high mortality risk within 6 months, or would\n             interfere with study compliance or data interpretation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "8 Months"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112994", 
            "org_study_id": "LAL-CL06", 
            "secondary_id": "2011-004287-30"
        }, 
        "intervention": {
            "arm_group_label": "sebelipase alfa", 
            "description": "Intravenous infusion of sebelipase alfa: 1mg/kg every other week", 
            "intervention_name": "sebelipase alfa", 
            "intervention_type": "Drug", 
            "other_name": "SBC-102"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Enzyme Replacement Therapy (ERT)", 
            "Lysosomal Storage Disease", 
            "Late Onset Lysosomal Acid Lipase (LAL) Deficiency", 
            "Acid cholesteryl ester hydrolase deficiency, type 2", 
            "Acid lipase disease", 
            "Cholesterol ester hydrolase deficiency", 
            "LAL Deficiency", 
            "LIPA Deficiency", 
            "Wolman disease", 
            "Additional relevant MeSH terms:", 
            "Cholesterol Ester Storage Disease", 
            "Wolman Disease", 
            "Metabolic Diseases", 
            "Lipidoses", 
            "Lipid Metabolism, Inborn Errors", 
            "Metabolism, Inborn Errors", 
            "Genetic Diseases, Inborn", 
            "Lysosomal Storage Diseases", 
            "Lipid Metabolism Disorders", 
            "Infant, Newborn, Diseases"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sayre", 
                    "country": "United States", 
                    "state": "Pennsylvania"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency", 
        "overall_contact": {
            "email": "emily.radomile@synageva.com", 
            "last_name": "Emily Radomile", 
            "phone": "781-357-9983"
        }, 
        "overall_contact_backup": {
            "email": "marina.escudero@synageva.com", 
            "last_name": "Marina Escudero", 
            "phone": "781-538-4844"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of adverse events (AEs), SAEs, and infusion-related reactions (IRRs);\nChanges from Baseline in 12-lead electrocardiograms (ECGs) and clinical laboratory tests;\nChanges in vital signs during and after infusion, relative to pre-infusion values;\nPhysical examination findings;\nUse of concomitant medications/therapies;\nCharacterization of anti-drug antibodies (ADAs);\nFunctional and overall development in patients \u2264 6 years of age will be assessed, as determined by Denver II scores.", 
            "measure": "The safety of sebelipase alfa in a more broad population of patients with LALD than have been previously studied.", 
            "safety_issue": "Yes", 
            "time_frame": "30 days after last study drug infusion (up to 96 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112994"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Decrease in LDL-C;\nDecrease in non-HDL-C;\nDecrease in triglycerides;\nIncrease in HDL-C", 
                "measure": "The effect of sebelipase alfa on lipid metabolism.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment period (up to 96 weeks)"
            }, 
            {
                "measure": "The effect of sebelipase alfa on growth parameters in pediatric patients presenting with evidence of growth delay.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment period (up to 96 weeks)"
            }, 
            {
                "description": "PK parameters include: Cmax, time to maximum concentration, area under the serum concentration vs. time curve from time zero to the last measurable time point, area under the serum concentration vs. time curve from time zero to infinity, terminal elimination half-life, serum clearance, and apparent volume of distribution.", 
                "measure": "The effect of sebelipase alfa on PK parameters.", 
                "safety_issue": "No", 
                "time_frame": "Week 0, Week 24, Week 48"
            }, 
            {
                "description": "Decrease in Child-Pugh status for patients with Child-Pugh class C or B at Baseline;\nDecreased United Kingdom Model for End-Stage Liver Disease (UK-ELD) score;\nImprovement in liver histopathology.", 
                "measure": "The effect of sebelipase alfa on liver function (including histopathology).", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of treatment period (up to 96 weeks)"
            }
        ], 
        "source": "Synageva BioPharma Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Synageva BioPharma Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}